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Abstract 
Background: Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular compli‑
cations. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. However, met‑
formin’s effects in patients with diabetic VC have not previously been characterized. The present study investigated 
the association between metformin use and lower‑limb arterial calcification in patients with type 2 diabetes and high 
cardiovascular risk.
Methods: The DIACART cross‑sectional cohort study included 198 patients with type 2 diabetes but without severe 
chronic kidney disease. Below‑the‑knee calcification scores were assessed by computed tomography and supple‑
mented by colour duplex ultrasonography. Data on anti‑diabetic drugs were carefully collected from the patients’ 
medical records and during patient interviews. Biochemical and clinical data were studied as potential confounding 
factors.
Results: Metformin‑treated patients had a significantly lower calcification score than metformin‑free patients 
(mean ± standard deviation: 2033 ± 4514 and 4684 ± 9291, respectively; p = 0.01). A univariate analysis showed 
that metformin was associated with a significantly lower prevalence of severe below‑the‑knee arterial calcifica‑
tion (p = 0.02). VC was not significantly associated with the use of other antidiabetic drugs, including sulfonylureas, 
insulin, gliptin, and glucagon like peptide‑1 analogues. A multivariate logistic regression analysis indicated that the 
association between metformin use and calcification score (odds ratio [95% confidence interval] = 0.33 [0.11–0.98]; 
p = 0.045) was independent of age, gender, tobacco use, renal function, previous cardiovascular disease, diabetes 
duration, neuropathy, retinopathy, HbA1c levels, and inflammation.
Conclusions: In patients with type 2 diabetes, metformin use was independently associated with a lower below‑the‑
knee arterial calcification score. This association may contribute to metformin’s well‑known vascular protective effect. 
Further prospective investigations of metformin’s potential ability to inhibit VC in patients with and without type 2 
diabetes are now needed to confirm these results.
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Background
Vascular calcification (VC) corresponds to the pathologi-
cal deposition of calcium-phosphate crystals in the vas-
culature, causing several adverse cardiovascular effects. 
Indeed, it is now clearly established that VC is associated 
with cardiovascular mortality (independently of other 
risks factors) in the general population and in patients 
with type 2 diabetes [1, 2]. Type 2 diabetes is known to 
induce VC, principally at the media tunica of the artery 
(medial calcific sclerosis) [3, 4]. Medial calcification 
principally occurs in patients with neuropathy [5], and 
tibial artery calcification contributes to peripheral artery 
occlusive disease—a leading risk factor for amputation in 
type 2 diabetes [6]. Hence, limiting or decreasing arterial 
wall calcification is an important therapeutic objective 
in patients with types 2 diabetes. However, medications 
specifically aimed at avoiding or delaying VC are not 
available.
On the cellular level, VC is an active process that 
involves many different stimuli and signalling pathways. 
Vascular smooth muscle cells (VSMCs) or circulat-
ing myeloid cells express bone-related proteins (such as 
Runx2, Msx2, and osteocalcin) and ultimately differen-
tiate into osteoblast-like cells [4, 7–9]. Beyond the pre-
ponderant role of calcium and phosphate homeostasis 
in VC, several specific factors have been associated with 
increased VC in patients with type 2 diabetes, such as 
high glucose concentration [10], advanced glycation end 
products [11], increased activity of the renin angiotensin 
system [12], and diabetic nephropathy [13]. The involve-
ment of these specific mechanisms suggests that medica-
tions aimed at controlling hyperglycaemia could protect 
against VC. Some studies have indeed reported a positive 
relationship between HbA1c levels on one hand and the 
coronary artery calcium score [14–16] and peripheral 
vascular calcification [17] on the other.
With regard to anti-diabetic medications, recently 
published data have highlighted metformin’s potential 
ability to reduce VC. In in vitro studies, exposure of rat 
aortic VSMCs to metformin was associated with a sig-
nificant reduction in trans differentiation and calcium 
deposition via the activation of AMP-activated protein 
kinase (AMPK) and endothelial nitric oxide synthase 
(eNOS) [18]. These results were confirmed in vivo in rats 
treated with vitamin D and nicotine, in which metformin 
reduced VC by restoring AMPK phosphorylation and 
eNOS expression [19]. Cai et al. described the underlying 
molecular mechanism in more detail in dual ApoE and 
AMPK1α1 knock-out mice; activation of AMPK1α1 in 
VSMCs was the main factor involved in metformin’s inhi-
bition of atherosclerotic calcification [20].
On the basis of these preclinical findings, we hypoth-
esized that metformin use could be associated with lower 
levels of VC in patients with type 2 diabetes. We there-
fore decided to study the association between metformin 
use and the below-the-knee arterial calcification score in 
a population of patients with type 2 diabetes.
Research design and methods
Study design
The protocol of the DIACART Study (for “Diabète et 
Calcification Arterielle”) has been described in detail 
elsewhere [21]. In brief, the study included 198 patients 
with type 2 diabetes attending the Cardiology and Dia-
betology Departments at Pitié-Salpêtrière University 
Hospital (Paris, France) over an 8-month period (from 
November 2011 to July 2012). The main inclusion cri-
teria were (i) type 2 diabetes, and (ii) high cardiovascu-
lar risk. This risk was defined as the presence of one or 
more of the following factors: coronary artery disease, 
peripheral arterial occlusive disease, and age  >50  years 
(for men) or >60 years (for women). The main exclusion 
criteria were (i) stage 4 or more chronic kidney disease, 
defined as a glomerular filtration rate estimated accord-
ing to the Modification of Diet in Renal Disease equation 
(eGFR-MDRD) ≤30 ml/min [22], (ii) type 1 diabetes, (iii) 
a history of lower-limb angioplasty or bypass. The study 
was performed in accordance with the principles of the 
Declaration of Helsinki. The study protocol was approved 
by the local independent ethic committee (Comité de 
Protection des Personnes “Ile de France VI”, Paris, France). 
Patients were provided with comprehensive information 
on the study’s objectives and procedures. All patients 
gave their written, informed consent to participation.
Study protocol
Clinical evaluations, laboratory blood and urine tests, 
multislice spiral CT scans, colour duplex ultrasonogra-
phy, and an interview focused on the patient’s treatments 
and comorbidities were performed during a 1-day hospi-
talization. Additional information on anti-diabetic drugs 
use was extracted from the patients’ medical records. All 
data were analyzed independently by physicians blinded 
to the patients’ other results. Peripheral neuropathy was 
evaluated according to the Neuropathy Disability Score 
(with a score  ≥6 considered to be abnormal). Previous 
cardiovascular disease was defined as a history of myo-
cardial infarction, stroke, or any invasive procedure for 
coronary artery disease.
Quantification of below‑the‑knee artery calcification
Below-the-knee artery calcification was assessed by 
scanning in the craniocaudal direction (from the patella 
to the ankle) with a 128-slice multi detector CT system 
(Somatom Definition Flash, Siemens Healthcare, Forch-
heim, Germany) in the absence of contrast agent. Each 
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3-mm cross-sectional slice was individually analyzed 
with Heartbeat CaScore software (Philips Healthcare, 
Eindhoven, The Netherlands). Each 1  mm2 area along 
below-the-knee arteries with ≥130 Hounsfield units was 
identified and multiplied by its density score (from 1 to 
4). The sum of the weighted areas was used to calculate 
the calcification score, according to Agatston’s method 
[23]. Calcification scores for the main below-the-knee 
arteries (the distal popliteal, anterior tibial, posterior tib-
ial, and peroneal arteries) were summed to give an overall 
calcification score.
Quantification of peripheral arterial occlusion and medial 
calcific sclerosis
Colour duplex ultrasonography was used to comprehen-
sively assess VC. Peripheral arterial occlusive disease 
was defined as occlusion or >70% stenosis in any artery 
from the abdominal tree down to the foot arteries. The 
severity of the stenosis was rated, with a score of 0 for no 
stenosis or <70% stenosis, a score of 2 for >70% stenosis, 
and a score of 3 for occlusion. The overall occlusion score 
(ranging from 0 to 39) was obtained by summing each 
individual artery score. Medial calcific sclerosis was also 
graded on the basis of ultrasound imaging, with a score 
of 0 point if not visible, a score of 1 if discontinuous, a 
score of 2 if continuous, and a score of 3 if the lumen was 
obstructed. Using the same method, an overall lower-
limb medial calcific sclerosis score was calculated (rang-
ing from 0 to 36).
Laboratory tests
Fasting blood were collected for measurement of HbA1c, 
glucose, ultrasensitive C-reactive protein, interleukin 6 
(IL-6), calcium, phosphate, creatinine, and urine samples 
for measurement of microalbuminuria.
Statistical analysis
Data are expressed as the mean  ±  standard deviation 
(SD) and median for quantitative variables or the number 
(percentage) for qualitative variables. Given that the cal-
cification scores were not normally distributed, a semi-
log scale was used for graphical representations. The 
study population was divided into metformin-treated 
and -non-treated groups, depending on the current 
prescription. Intergroup comparisons were performed 
with a χ2 test for qualitative variables, and Student’s T 
test or the Mann–Whitney test for continuous vari-
ables. χ2 tests were also used to compare the frequency 
of metformin prescription in calcification score tertiles. 
For logistic regression analyses, patients were divided 
into two groups as a function of the severity of below-
the-knee calcification (a score of 0–166 Agatston units 
[corresponding to the first tertile] vs. a score of  >166). 
Univariate logistic regression analyses were used to assess 
the association between the below-the-knee calcification 
score category and metformin use. To assess the inde-
pendence of this association (particularly with regard to 
age and renal status), we performed a multivariate logis-
tic regression that included both variables identified in 
univariate analyses and relevant clinical variables. Mark-
ers of the severity of diabetes (the duration of diabetes, 
a history of retinopathy or neuropathy, the HbA1c level, 
and insulin treatment) were always entered as potential 
factors explaining the intensity of calcification. Further-
more, the likelihood ratio technique was used to test 
the model’s robustness. Patients with missing data were 
excluded solely from analyses in which the correspond-
ing parameter was specifically included. For all tests, the 
threshold for statistically significance was set to p ≤ 0.05. 
All statistical analyses were performed using SPSS soft-
ware (version 18.0, SPSS Inc., Chicago, IL, USA). Graphs 
were created using SPSS software (version 18.0, SPSS 
Inc., Chicago, IL, USA) or GraphPad Prism (version 5.0, 
GraphPad Software, La Jolla California, USA).
Results
Baseline characteristics
The main clinical and biochemical characteristics for 
the study population as a whole and for the two sub-
groups are summarized in Table  1. There were a few 
missing data for the medial calcific sclerosis score (n = 2 
patients), IL-6 (n =  1). The study included 198 patients 
with male/female ratio: 3.95:1; and a mean ± SD age of 
64.4  ±  8.4  years. The metformin group comprised 161 
patients (81.3%). The mean diabetes duration was similar 
in the two subgroups (around 14  years). Patients in the 
metformin group were significantly younger, and had a 
slightly higher eGFR-MDRD, less neuropathy, and lower 
serum IL-6. It is noteworthy that patients in the met-
formin group tended to have less retinopathy and a lower 
peripheral arterial occlusion score, although the differ-
ence was not statistically significant. Other variables did 
not differ significantly when comparing the two groups. 
Metformin was the most frequently prescribed drug, fol-
lowed by sulfonylureas and related drugs (52.0%), insulin 
(47.5%), and gliptin or GLP-1 analogues (31.8%).
Association between below‑the‑knee calcification scores 
and metformin treatment
The mean calcification score was about two-fold lower 
in patients with a current metformin prescription than 
in those without (Table  1; Fig.  1). Likewise, the medial 
calcific sclerosis score was significantly lower in the met-
formin group. Metformin was prescribed in 90.9% of 
the patients in the lowest calcification tertile but in only 
78.8 and 74.2% of the patients in the second and the last 
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tertiles, respectively. This difference was statistically sig-
nificant when comparing all three tertiles (p = 0.04), the 
first and second tertiles (p = 0.05), and the first and last 
tertiles (p  =  0.01), but not the second and last tertiles 
(p =  0.54). A univariate logistic regression analysis cor-
roborated our finding that metformin prescription was 
associated with a lower likelihood of being in the second 
or last calcification tertiles (odds ratio (OR) [95% confi-
dence interval (CI)] = 0.33 [0.13–0.83]; p = 0.02, Fig. 2). 
In contrast, the use of other antidiabetic drugs (including 
insulin), was not associated with differences in the calcifi-
cation scores (Fig. 2).
Independence of the association between metformin 
prescription and VC
In univariate analyses, the clinical and biochemical 
characteristics significantly associated with the prob-
ability of having a higher calcification score than the 
first tertile were as follows: age (OR [95% CI] per 5 years 
increment  =  1.44 [1.18–1.75]; p  <  0.001), male gender 
(OR [95% CI]  =  2.44 [1.20–4.95]; p  =  0.014), previous 
cardiovascular disease (OR [95% CI] = 3.29 [1.74–6.21]; 
p < 0.001), tobacco use (OR [95% CI] = 1.87 [1.03–3.41]; 
p = 0.041), retinopathy (OR [95% CI] = 2.48 [1.03–5.99]; 
p  =  0.044), and a low eGFR-MDRD (OR [95% CI] per 
10 ml/min increment = 0.82 [0.71–0.96]; p = 0.012). In 
a multivariate analysis, metformin remained significantly 
associated with the calcification scores, independently 
of age, gender, previous cardiovascular disease, eGFR-
MDRD, tobacco use, diabetes duration, neuropathy, 
retinopathy, HbA1c, serum IL-6, and insulin prescription 
(Fig. 3). When the model was simplified by applying the 
likelihood ratio method, metformin treatment, age, male 
gender, previous cardiovascular disease, and retinopa-
thy remained significantly associated with VC (data not 
shown).
Discussion
The present study is the first to demonstrate that met-
formin prescription in patients with type 2 diabetes is 
associated with lower levels of below-the-knee arte-
rial calcification. This association was found to be 
Table 1 Demographic characteristics of the total study population and the metformin subgroups
Data are expressed as the mean ± SD (median) for quantitative variables, and as the number (percentage) for qualitative variables
CVD cardiovascular disease, AU Agatston unit, MCS medial calcific sclerosis, eGFR-MDRD estimated glomerular filtration rate according to the Modification of Diet in 
Renal Disease equation, HbA1c glycated haemoglobin, us-CRP ultrasensitive C-reactive protein, LDL low-density lipoprotein, HDL high-density lipoprotein
Total population Metformin‑treated Metformin‑untreated p‑value
n 198 161 37
Age (y) 64.4 ± 8.4 (65) 63.8 ± 8.2 (64) 66.9 ± 9 (66) 0.040
Males 158 (80%) 132 (82%) 26 (70%) 0.109
Diabetes duration (y) 14.6 ± 9.3 (13) 14.7 ± 9.1 (13) 14.2 ± 10.6 (12) 0.785
Body mass index (kg/m2) 29.2 ± 5.3 (28.0) 29.1 ± 5.2 (28.2) 29.3 ± 5.4 (29.4) 0.829
Previous CVD 139 (70%) 112 (70%) 27 (73%) 0.683
Hypertension 163 (82%) 131 (81%) 32 (86%) 0.462
Insulin treatment 94 (47%) 66 (41%) 28 (76%) 0.001
Neuropathy 31 (15%) 21 (13%) 10 (27%) 0.035
Retinopathy 37 (19%) 26 (6%) 11 (30%) 0.056
Current or ex‑smoker 119 (60%) 99 (61%) 20 (54%) 0.405
Calcification score (AU) 2528 ± 5779 (524) 2033 ± 4514 (434) 4684 ± 9291 (1044) 0.012
MCS score 19.1 ± 10.9 (24) 18 ± 10.7 (20) 23.6 ± 10.8 (24) 0.010
Occlusion score 3.5 ± 5.3 (0) 3.2 ± 5.1 (0) 4.6 ± 6.1 (3) 0.073
eGFR‑MDRD (ml/min) 76 ± 20 (76) 77 ± 20 (77) 70 ± 18 (71) 0.048
Microalbuminuria (mg/l) 166 ± 841 (23) 178 ± 924 (23) 110 ± 255 (17) 0.658
HbA1c (%/mmol/mol) 7.8 ± 1.5 (7.5)/62 ± 16 (58) 7.8 ± 1.4 (7.5)/62 ± 15 (58) 8.0 ± 1.7 (7.5)/64 ± 19 (58) 0.521
Blood glucose (mmol/l) 8.2 ± 2.8 (7.8) 8.2 ± 2.8 (7.8) 7.9 ± 2.8 (7.6) 0.590
Calcium (mmol/l) 2.32 ± 0.11 (2.32) 2.32 ± 0.11 (2.32) 2.31 ± 0.14 (2.31) 0.738
Phosphate (mmol/l) 1.02 ± 0.15 (1.02) 1.02 ± 0.15 (1.02) 1.04 ± 0.17 (1.02) 0.390
us‑CRP (mg/l) 2.2 ± 2.5 (1.2) 2.1 ± 2.4 (1.2) 2.7 ± 2.9 (1.5) 0.448
Interleukin‑6 (pg/ml) 5.1 ± 22.2 (2.9) 3.5 ± 3.6 (2.8) 12.4 ± 50.5 (3.3) 0.033
LDL cholesterol (g/l) 1.93 ± 0.74 (1.81) 1.93 ± 0.76 (1.78) 2.04 ± 0.67 (1.89) 0.213
HDL cholesterol (g/l) 1.08 ± 0.33 (1.06) 1.06 ± 0.34 (1.01) 1.15 ± 0.28 (1.17) 0.128
Triglycerides (g/l) 1.58 ± 1.05 (1.26) 1.62 ± 1.11 (1.24) 1.42 ± 0.72 (1.42) 0.628
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independent of age, gender, renal function, diabetes 
duration and complications of diabetes. The majority of 
study participants (81.3%) were taking metformin; this 
reflects compliance with current guidelines on diabetes 
treatment and trends in the prescription of antidiabetic 
drugs [24]. Despite the fact that the number of patients 
not receiving metformin was rather small, it should be 
noted that the association between metformin use and 
lower calcification remained statistically significant in a 
multivariate analysis. Moreover, none of the other anti-
diabetic drugs taken were significantly associated with 
the calcification scores—suggesting that this property is 
specific to metformin.
The American Diabetes Association and European 
Association for the Study of Diabetes both recommend 
metformin as the first-line pharmacological treatment for 
type 2 diabetes [25], in view of the drug’s association with 
lower cardiovascular morbidity and mortality rates [26]. 
The results of the UK Prospective Diabetes Study showed 
that early intervention with metformin in patients with 
type 2 diabetes decreased the all-cause mortality rate by 
36% (due to a decrease in macrovascular events) [27]. 
Metformin treatment in type 2 diabetes patients was 
effective in reducing the carotid intima-media thick-
ness [28, 29] and is even associated with lower mortality 
rates in patients with established atherothrombosis [30]. 
Interestingly, metformin treatment has been shown to 
increase lower arterial flow in diabetes-free patients with 
peripheral vascular disease [31]—suggesting that the 
drug’s protective cardiovascular effect is not solely due 
to its action on blood glucose levels. The mechanisms 
involved in metformin-mediated cardiovascular protec-
tion have not yet been fully characterized. On the molec-
ular level, it has been suggested that activation of AMPK 
Fig. 1 The calcification scores in patients with a current prescrip‑
tion of metformin (n = 161) or not (n = 37). Calcification scores for 
below‑the‑knee arteries were calculated using Agatston’s method. 
The median log calcification score was 2.637 in the metformin group 
and 3.019 in the non‑metformin group (p = 0.012)
Fig. 2 Association of antidiabetic drugs with below‑the‑knee arterial calcification. a The histogram represents the frequency of each antidiabetic 
drug in the cohort (n = 198). The black bars indicate patients treated with metformin (either alone or in combination with other medications). The 
white bars indicate patients treated with other antidiabetic drugs but not metformin. The number of patients is indicated on the different bars. b 
Univariate logistic regression, with a focus on pharmacological diabetic therapy (n = 198). Among the antidiabetic drugs, only the prescription of 
acarbose (in 4 patients) was not assessed in logistic analyses. GLP‑1 glucagon like peptide‑1
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might have a central role. AMPK phosphorylation by 
metformin improves the lipid profile [32], decreases oxi-
dative stress [33], and protects against ischemia by main-
taining ATP energy balance and increasing eNOS activity 
[34]. Recently published data show that metformin has a 
protective effect on endothelial function and angiogen-
esis. In streptozotocin-induced diabetic mice, metformin 
improved the function and increased the number of bone 
marrow endothelial progenitor cells (EPCs) [35]. This 
result has been confirmed in patients with type 1 diabetes 
in the MERIT study [36]. In cellular models of diabetes, 
metformin’s pro-angiogenic endothelial properties were 
found to be related to (i) AMPK/eNOS activity [35], (ii) 
a decrease in miR-34a levels and an increase in sirtuin1 
expression [37], and (iii) secretion of vascular endothelial 
growth factor A together with a reduction in mRNA lev-
els of angiogenetic inhibitors [38]. It was recently hypoth-
esized that the EPCs’ loss of proangiogenic function in 
type 1 and 2 diabetes may lead to an osteogenic shift to 
myeloid calcifying cells, which thus links endothelial dys-
function and VC [39].
Vascular calcification is also associated with higher 
cardiovascular morbidity in patients with diabetes [3]. 
A putative metformin-related decrease in VC may thus 
contribute to cardiovascular protection. In below-the-
knee arteries, VC favours peripheral arterial occlusive 
disease and thus lower-limb amputation [6, 21]. Delay-
ing lower-limb VC through the use of metformin might 
decrease the risk of amputation. This is of particular 
interest, since a recent analysis of the UK QResearch 
database suggested that metformin monotherapy reduces 
the risk of leg amputation relative to sulfonylureas or 
insulin monotherapy [40].
By demonstrating an inverse relationship between met-
formin use and VC in patients with type 2 diabetes, our 
results are in line with recent in  vitro and in  vivo data 
demonstrating that metformin can inhibit VC. At pre-
sent, this effect is thought to be related to AMPK acti-
vation [18–20]. Indeed, it was recently suggested that 
AMPKα1 activation phosphorylates STAT-1, promotes 
Runx2 proteasome degradation and thus decreases the 
differentiation of VSMCs into calcifying cells [20]. The 
AMPK1-related decrease in oxidative stress in endothe-
lial cells may also reflect relevant protection against VC, 
since hydrogen peroxide is known to promote pheno-
typic switching of VSMCs by activating RUNX2 [41]. 
Fig. 3 Multivariate logistic regression analysis: variables independently and significantly associated with below‑the‑knee arterial calcification 
(n = 198). The figure presents the odds ratio [95% CI] for each variable. Variables significantly associated with VC in univariate analyses and variables 
with relevance to diabetes were included in the multivariate model. CVD cardiovascular disease, eGFR‑MDRD glomerular filtration rate estimated 
using the Modification of Diet in Renal Disease equation, HbA1c glycated haemoglobin, IL‑6 interleukin‑6
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In  vitro, metformin’s AMPK phosphorylation reduces 
endothelial cells’ production of IL-6, a known inducer of 
VC [42]. Metformin treatment of patients with polycys-
tic ovary syndrome is associated with lower serum IL-6 
levels [43]. This was also the case in the present study, 
suggesting that IL-6 serum concentration reflects activa-
tion of AMPK by metformin. However, the fact that the 
association between metformin use and lower peripheral 
calcification was independent of IL-6 levels indicates that 
this was not the main mechanism.
We also found that metformin-treated patients had a 
higher eGFR-MDRD and were younger, less likely to be 
taking insulin and to have neuropathy, when compared 
with metformin-free patients. Given that age and eGFR-
MDRD were also correlated with calcification score, the 
two parameters might be confounding factors that explain 
the intergroup differences in the peripheral calcification 
score. However, the results of our adjusted multivari-
ate analysis indicate that the inverse association between 
VC and metformin use is independent of age and eGFR-
MDRD. It has now been clearly established that chronic 
kidney disease (CKD) accelerates VC [13]. As severe CKD 
is currently a contraindication for metformin prescription 
(due to a risk of lactic acidosis), diabetic CKD may consti-
tute a lost opportunity to delay VC. A potential protective 
effect of metformin against VC would be a further argu-
ment in favour of maintaining metformin use in patients 
with diabetic nephropathy, since the additional risk of lac-
tic acidosis due to metformin remains a subject to debate 
[44, 45]. With a view to shedding light on this attractive 
prospect of metformin use in CKD, evaluation in large 
clinical trials is now needed.
The present study’s limitations include the cross 
sectional design, the relatively small number of non-
metformin users, and the lack of data on metformin 
concentrations. A specific, prospective, randomized or 
case-controlled study might overcome these limitations. 
The present study’s strengths include its assessment of 
arterial calcification with a highly sensitive CT scan and 
ultrasonography, and a thorough analysis of the pre-
scribed antidiabetic drugs.
Conclusions
In conclusion, our study of patients with type 2 diabetes 
and high cardiovascular risk demonstrated that among 
antidiabetic drugs, only metformin treatment is nega-
tively and independently associated with the severity of 
lower-limb artery calcification. The negative association 
between metformin use and VC may contribute (at least 
in part) to the drug’s well-known vascular protective 
effect. Our findings suggest that metformin use may con-
stitute the best currently available strategy for delaying 
VC in type 2 diabetes, and may reinforce the justification 
for its first-line prescription in type 2 diabetes. Outside 
the field of diabetes, metformin might be a potential 
treatment option for other patients at risk of developing 
VC, such as those with CKD. These promising observa-
tions require confirmation in prospective studies.
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